{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T11:20:14Z","timestamp":1720178414242},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.lungcan.2016.12.010","type":"journal-article","created":{"date-parts":[[2016,12,22]],"date-time":"2016-12-22T08:00:54Z","timestamp":1482393654000},"page":"75-78","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Is clarithromycin a potential treatment for cachexia in people with lung cancer? A feasibility study"],"prefix":"10.1016","volume":"104","author":[{"given":"Sarah","family":"Awan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Crosby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Potter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivo","family":"Hennig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Baldwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehluli","family":"Ndlovu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Paradine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Wilcock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2016.12.010_bib0005","article-title":"Estimation of cachexia among cancer patients based on four definitions","author":"Fox","year":"2016","journal-title":"J. Oncol."},{"key":"10.1016\/j.lungcan.2016.12.010_bib0010","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1038\/sj.bjc.6601781","article-title":"Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?","volume":"90","author":"Ross","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2016.12.010_bib0015","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/1097-0142(197701)39:1<303::AID-CNCR2820390147>3.0.CO;2-U","article-title":"Survival with inoperable lung cancer: an integration of prognostic variables based on simple clinical criteria","volume":"39","author":"Lanzotti","year":"1977","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2016.12.010_bib0020","first-page":"10","article-title":"Flores-Estrada D, Diaz-Romero C, et al., Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study","volume":"21","author":"Arrieta","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.lungcan.2016.12.010_bib0025","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1517\/14728214.2012.652946","article-title":"Editorial update on emerging drugs for cancer cachexia","volume":"17","author":"Murphy","year":"2012","journal-title":"Expert Opin. Emerging Drugs"},{"key":"10.1016\/j.lungcan.2016.12.010_bib0030","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1200\/JCO.2012.48.3149","article-title":"Clinical trials of cancer cachexia therapy, now and hereafter","volume":"10","author":"Baracos","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2016.12.010_bib0035","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1159\/000239580","article-title":"Significant survival benefit to patients with advanced non-small cell lung cancer from treatment with clarithromycin","volume":"43","author":"Mikasa","year":"1997","journal-title":"Chemotherapy"},{"key":"10.1016\/j.lungcan.2016.12.010_bib0040","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1159\/000048556","article-title":"Anti-cachectic effect of clarithromycin for patients with unresectable non-small cell lung cancer","volume":"47","author":"Sakamoto","year":"2001","journal-title":"Chemotherapy"},{"key":"10.1016\/j.lungcan.2016.12.010_bib0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0041883","article-title":"The relationships between body composition and the systemic inflammatory response in patients with primary operable colorectal cancer","volume":"7","author":"Richards","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.lungcan.2016.12.010_bib0050","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ctrv.2012.08.003","article-title":"The systemic inflammation-based Glasgow prognostic score: a decade of experience in patients with cancer","volume":"39","author":"McMillan","year":"2013","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.lungcan.2016.12.010_bib0055","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/bjc.2014.90","article-title":"Cancer and systematic inflammation: treat the cancer and treat the host","volume":"110","author":"Roxburgh","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2016.12.010_bib0060","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s004330050068","article-title":"Clarithromycin is a potent inhibitor of tumor-induced angiogenesis","volume":"197","author":"Yatsunami","year":"1997","journal-title":"Res. Exp. Med. (Berl.)"},{"key":"10.1016\/j.lungcan.2016.12.010_bib0065","first-page":"2259","article-title":"Effect of clarithromycin treatment of natural killer cell activity in patients with advanced non-small cell lung cancer","volume":"25","author":"Sakamoto","year":"1998","journal-title":"Gan To. Kagaku Ryoho"},{"key":"10.1016\/j.lungcan.2016.12.010_bib0070","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000098426","article-title":"Clarithromycin suppresses invasiveness of human lung adenocarcinoma cells","volume":"53","author":"Wada","year":"2007","journal-title":"Chemotherapy"},{"key":"10.1016\/j.lungcan.2016.12.010_bib0075","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3332\/ecancer.2015.513","article-title":"Repurposing drugs in oncology (ReDO) \u2212clarithromycin as an anti-cancer agent","volume":"9","author":"Van Nuffel","year":"2015","journal-title":"ecancer"},{"key":"10.1016\/j.lungcan.2016.12.010_bib0080","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/j.jacc.2015.09.029","article-title":"The role of macrolide antibiotics in increasing cardiovascular risk","volume":"66","author":"Cheng","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.lungcan.2016.12.010_bib0085","doi-asserted-by":"crossref","first-page":"7438","DOI":"10.1038\/srep07438","article-title":"Azithromycin suppresses CD4(+) T-cell activation by direct modulation of mTOR activity","volume":"4","author":"Ratzinger","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lungcan.2016.12.010_bib0090","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3892\/ijo.2015.3237","article-title":"Macrolides sensitize EGFR-TKI-induced non-apoptotic cell death via blocking autophagy flux in pancreatic cancer cell lines","volume":"48","author":"Mukai","year":"2016","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.lungcan.2016.12.010_bib0095","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMoa1104623","article-title":"Azithromycin for prevention of exacerbations of COPD","volume":"365","author":"Albert","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2016.12.010_bib0100","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jama.2013.1937","article-title":"Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial","volume":"309","author":"Altenburg","year":"2013","journal-title":"JAMA"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500216305773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500216305773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T20:55:35Z","timestamp":1568667335000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500216305773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":20,"alternative-id":["S0169500216305773"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2016.12.010","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is clarithromycin a potential treatment for cachexia in people with lung cancer? A feasibility study","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2016.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}